Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
GlaxoSmithKline
This is a phase I, an open label, single dose and parallel group study to assess short term pharmacodynamics and safety of GSK933776. The effect on the beta amyloid levels will be assessed in early (MCI) and mild Alzheimer's disease (AD) patients after a single dose of GSK933776 by i.v. administration.
Age
55–85
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Probable mild Alzheimer's disease (MMSE 20-26) or mild cognitive impairment
Increase in total tau or p-tau in CSF
Decrease in amyloid beta in CSF
Stable dose of cholinesterase inhibitors, memantine or selegine or no treatment
Body weight less than 120 kg
Willingness to comply with contraceptive methods if self or partner is of child-bearing potential
You may not be if
Any other cause of dementia
Other significant neurologic or psychiatric illness
Hachinski Ischemia Score \>4
More than 3 microbleeds on MRI
Type 2 diabetes not controlled by diet
Risk of cerebrovascular disease, cerebral haemorrhage or stroke
History of systemic autoimmune disease
Use of platelet anti-aggregates or anti-coagulants (Aspirin up to 325 mg/day is allowable)
Use of chronic corticosteroids
Uncontrolled hypertension in spite of antihypertensive medications
Renal or hepatic insufficiency or clinically significant anaemia
In nursing home care
Contraindications to lumbar puncture or MRI
Prior participation in therapeutic studies only after adequate wash-out period
